Silicosis

Summary

Silicosis (MONDO:0005960) is a disease and 17 clinical trials. Top therapeutic interventions include pirfenidone. A subtype of pneumoconiosis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 17

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	silicosis
Mondo ID	MONDO:0005960
EFO	EFO:0007485
MeSH	D012829
DOID	DOID:10325
NCIT	C3369
SNOMED CT	805002
UMLS	C0037116
MedGen	20758
GARD	0007647
Is cancer (heuristic)	no

Also known as: accelerated silicosis · acute silicosis · chronic silicosis · experimental silicosis · pneumoconiosis due to silica · silicosis · silicotuberculosis

Disease family

This is a subtype of pneumoconiosis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › respiratory system disorder › lower respiratory tract disorder › lung disorder › interstitial lung disease › pneumoconiosis › silicosis

Related subtypes (13): mixed mineral dust pneumoconiosis, baritosis, pneumoconiosis due to talc, slate pneumoconiosis, Caplan syndrome, anthracosilicosis, anthracosis, byssinosis, pulmonary hemosiderosis, chronic beryllium disease, asbestosis, mixed dust pneumoconiosis, graphite pneumoconiosis

Subtypes (2): silicotuberculosis, silicosiderosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated or in trials for this disease

1 approved drug — disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Status
Isoniazid	Approved (phase 4)

Clinical trials & evidence

Clinical trials

Clinical trials: 17.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	12
PHASE2	2
PHASE3	1
PHASE1/PHASE2	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02430259	PHASE3	COMPLETED	Efficacy of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention
NCT01977131	PHASE1/PHASE2	COMPLETED	Safety Study of Autologous Bone Marrow Stromal Cells With Modification by Hepatocyte Growth Factor to Treat Silicosis
NCT04161014	PHASE2	UNKNOWN	The Nintedanib in Progressive Pneumoconiosis Study (NiPPS): a Collaborative NSW Treatment Trial
NCT05118256	PHASE2	UNKNOWN	Pirfenidone for the Reduction of Metabolic, Inflammatory and Fibrogenic Activity in Complicated Silicosis
NCT06011785	EARLY_PHASE1	UNKNOWN	Using Silica 12CH to Mitigate the Effects and Symptoms of Silicosis in Brazil
NCT06403800	Not specified	RECRUITING	Silicosis and Silicotuberculosis Among Small Scale Gemstone Miners in Northern Tanzania
NCT06922916	Not specified	NOT_YET_RECRUITING	Perioperative Risk Factors Related to the Prognosis of Lung Transplantation: A Retrospective Study
NCT00005280	Not specified	COMPLETED	Specialized Center of Research in Occupational and Immunologic Lung Disease
NCT01329003	Not specified	UNKNOWN	DNA-damage Pathways in Workers Exposed to Silica (Caesar Stone)
NCT01338064	Not specified	UNKNOWN	Oxidative Stress Biomarkers to Monitor and Early Detect Health Impairment in Workers Exposed to Silica (Caesar Stone)
NCT01725971	Not specified	COMPLETED	Oscillation Mechanics of the Respiratory System in Never-smoking Patients With Silicosis
NCT02794701	Not specified	COMPLETED	Comprehensive Risk Assessment of People With Silicosis: A Population-based Study
NCT04205708	Not specified	COMPLETED	Screening Strategy for Early Diagnosis of Silicosis in At-Risk Populations in Oklahoma
NCT05402176	Not specified	UNKNOWN	The SHIELD Whole Lung Lavage Study
NCT05538299	Not specified	UNKNOWN	Silicosis Treatment, Action, Screening and Surveillance in Rwanda Trials
NCT05546944	Not specified	UNKNOWN	The SHIELD Study-silicosis
NCT06090370	Not specified	COMPLETED	Reducing Silica Exposure Among Brick Kiln Workers in Nepal

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PIRFENIDONE	4	1